Corona Remedies has lined up commercial agreements with partners across Europe, the UK, and other international markets and expects to begin supplying them from its new ₹130-crore EU-GMP-approved hormone manufacturing facility by FY29, with regulatory dossier filings scheduled for November-December this year.
The Ahmedabad-based pharmaceutical company said it has completed bioequivalence studies and is in the final stages of preparing regulatory dossiers, which will be submitted to overseas partners for filing by the end of 2026. The approval process is expected to take 12-18 months, paving the way for commercial supplies to regulated international markets from FY29.
“The hormonal plant has just started on June 30. We are in the final stage of developing the dossiers. By November-December 2026 we will be ready with the dossiers after completion of bioequivalence studies. We have already done a lot of promising agreements with partners. We will send these dossiers to the concerned countries for registration, and it will take another 12-18 months. We are projecting FY28-FY29 to kick off this plant at an international level, and we have high hopes from the international market,” Founder and Managing Director Nirav Mehta said during the company’s earnings call on Monday. The company said the new facility follows a “one world, one quality” manufacturing philosophy and will cater to both domestic and international markets. Management said Corona has already invested around Rs 130 crore in the EU-GMP-approved hormone manufacturing plant.
